Evidence map›Paper›PMID 38223588›Full record

SynthesisAfrican health sciences2023

Garlic supplementation for the treatment of chronic liver disease: a meta-analysis of randomized controlled trials.

Liu Xiaohui, Li Jinqi, Xie Xiaofang, Shi Zhiqiang, Niu Renxiu

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in African health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Liu XiaohuiCollege of traditional Chinese medicine, Inner Mongolia Medical University, Hohhot, 010110, China.
Li JinqiDepartment of Pharmacy, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, 610072 Chengdu, China.
Xie XiaofangDepartment of Pharmacy, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, 610072 Chengdu, China.
Shi ZhiqiangCollege of traditional Chinese medicine, Inner Mongolia Medical University, Hohhot, 010110, China.
Niu RenxiuCollege of traditional Chinese medicine, Inner Mongolia Medical University, Hohhot, 010110, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The efficacy of garlic supplementation for chronic liver disease remains controversial. We conduct a meta-analysis to explore the influence of garlic supplementation versus placebo on the treatment of chronic liver disease. Methods: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through September 2021 for randomized controlled trials (RCTs) assessing the efficacy of garlic supplementation versus placebo for chronic liver disease. This meta-analysis is performed using the random-effect model. Results: Four RCTs and 212 patients are included in the meta-analysis. Overall, compared with control group for chronic liver disease, garlic supplementation is associated with significantly reduced alanine aminotransferase (ALT), aspartate-aminotransferase (AST), total cholesterol, low density lipoprotein (LDL) and weight, but demonstrates no substantial impact on the incidence of adverse events. Conclusions: Garlic supplementation is effective to treat chronic liver disease.

Indexed as

GarlicNon-alcoholic Fatty Liver DiseaseAntioxidantsDietary SupplementsHumansRandomized Controlled Trials as TopicAntioxidantschronic liver diseaseGarlicmeta-analysisrandomized controlled trials

Identifiers

PMID38223588
PMCPMC10782365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.